749931-20-2

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Bromo-2-fluoro-5-methoxybenzaldehyde is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. Its unique structure allows for the development of new molecules with potentially useful biological properties, making it a valuable component in drug discovery and medicinal chemistry.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-bromo-2-fluoro-5-methoxybenzaldehyde serves as a key building block for the creation of new molecules with potential therapeutic applications. Its diverse reactivity and structural features enable researchers to explore novel chemical entities that may lead to the development of innovative treatments and therapies.
Used in Drug Development:
4-Bromo-2-fluoro-5-methoxybenzaldehyde plays a crucial role in drug development, as its unique structure and reactivity contribute to the design and synthesis of new drug candidates. Its versatility allows for the exploration of various chemical modifications, which can lead to the optimization of drug properties and the discovery of more effective and safer medications.
Used in Organic Chemistry:
As an aromatic aldehyde derivative, 4-bromo-2-fluoro-5-methoxybenzaldehyde is a valuable tool for organic chemists in the creation of new chemical entities. Its reactivity and structural features make it an ideal starting material for the synthesis of complex organic compounds, contributing to the advancement of organic chemistry and the development of new materials and applications.

Upstream product

• 7726-95-6 bromine 
• 105728-90-3 2-fluoro-5-methoxybenzaldehyde 
• 4885-02-3 Dichloromethyl methyl ether 
• 452-08-4 2-bromo-4-fluoro-1-methoxybenzene 

Downstream Products

• 1620677-51-1 4-bromo-2-fluoro-5-methoxybenzoic acid 
• 749931-19-9 (4-Bromo-2-fluoro-5-methoxy-phenyl)-methanol 

Relevant academic research and scientific papers

COMPOUNDS FOR MODULATING SPLICING

Described herein are agents that modify splicing of pre-mRNA and methods of making and using the same.

SUBSTITUTED CHROMEN-4-ONE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The present invention provides novel compounds having the general formula: (I) wherein R1 to R10, Gi, G2 and m are as described herein, compositions including the impounds and methods of using the compounds for the treatment of hepatitis B.

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).